New Psychoactive Substances: Which Biological Matrix Is the Best for Clinical Toxicology Screening?

被引:6
|
作者
Wagmann, Lea [1 ]
Jacobs, Cathy M. [1 ]
Meyer, Markus R. [1 ]
机构
[1] Saarland Univ, Ctr Mol Signaling PZMS, Inst Expt & Clin Pharmacol & Toxicol, Dept Expt & Clin Toxicol, Kirrberger Str Bldg 46, D-66421 Homburg, Germany
关键词
new psychoactive substances; drugs of abuse; mass spectrometry; clinical toxicology; RESOLUTION MASS-SPECTROMETRY; PACKED SORBENT; EXHALED BREATH; ORAL FLUID; AMPHETAMINES; URINE; DRUGS; ABUSE; BLOOD; MICROEXTRACTION;
D O I
10.1097/FTD.0000000000000974
中图分类号
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号
1001 ;
摘要
Background: Every year, more new psychoactive substances (NPSs) emerge in the market of the drugs of abuse. NPSs belong to various chemical classes, such as synthetic cannabinoids, phenethylamines, opioids, and benzodiazepines. The detection of NPSs intake using different types of biological matrices is challenging for clinical toxicologists because of their structural diversity and the lack of information on their toxicokinetics, including their metabolic fate. Methods: PubMed-listed articles reporting mass spectrometry-based bioanalytical approaches for NPSs detection published during the past 5 years were identified and discussed. Furthermore, the pros and cons of using common biological matrices in clinical toxicology (CT) settings to screen for NPSs are highlighted in this review article. Results: Twenty-six articles presenting multianalyte screening methods for use in the field of CT were considered. The advantages and disadvantages of different biological matrices are discussed with a particular view of the different analytical tasks in CT, especially emergency toxicology. Finally, an outlook introduces the emerging trends in biosamples used in CT, such as the exhaled breath. Conclusions: Blood and urine represent the most common biological matrices used in a CT setting; however, reports concerning NPSs detection in alternative matrices are also available. Noteworthy, the selection of the biological matrix must depend on the clinician's enquiry because the individual advantages and disadvantages must be considered.
引用
收藏
页码:599 / 605
页数:7
相关论文
共 50 条
  • [1] Clinical value of analytical testing in patients presenting with new psychoactive substances intoxication
    Grafinger, Katharina Elisabeth
    Liechti, Matthias E.
    Liakoni, Evangelia
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2020, 86 (03) : 429 - 436
  • [2] The Toxicology of New Psychoactive Substances: Synthetic Cathinones and Phenylethylamines
    Tyrkko, Elli
    Andersson, Mikael
    Kronstrand, Robert
    THERAPEUTIC DRUG MONITORING, 2016, 38 (02) : 190 - 216
  • [3] DEVELOPMENT AND APPLICATION OF A RAPID SCREENING METHOD FOR DETERMINATION OF NEW PSYCHOACTIVE SUBSTANCES AND THEIR METABOLITES IN URINE
    Shestakova, Kseniia Mikhailovna
    Savchuk, Sergey Alexandrovich
    Mesonzhnik, Natalia Vladimirovna
    Kuharenko, Alexey Vladimirovich
    Appolonova, Svetlana Alexandrovna
    PERIODICO TCHE QUIMICA, 2019, 16 (33): : 206 - 224
  • [4] High-performance liquid chromatography coupled to Orbitrap mass spectrometry for screening of common new psychoactive substances and other drugs in biological samples
    Nie, Manqing
    Zhang, Tianai
    Wang, Xuan
    Zhao, Xuan
    Luo, Chunying
    Wang, Lian
    Zou, Xiaoli
    JOURNAL OF FORENSIC SCIENCES, 2024, 69 (06) : 2171 - 2179
  • [5] New challenges and innovation in forensic toxicology: Focus on the "New Psychoactive Substances"
    Favretto, Donata
    Pascali, Jennifer P.
    Tagliaro, Franco
    JOURNAL OF CHROMATOGRAPHY A, 2013, 1287 : 84 - 95
  • [6] Screening methods for rapid determination of new psychoactive substances (NPS) in conventional and non-conventional biological matrices
    Graziano, Silvia
    Anzillotti, Luca
    Mannocchi, Giulio
    Pichini, Simona
    Busardo, Francesco Paolo
    JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS, 2019, 163 : 170 - 179
  • [7] New Psychoactive Substances: A Canadian perspective on emerging trends and challenges for the clinical laboratory
    Miller, Jessica J.
    Yazdanpanah, Mehrdad
    Colantonio, David A.
    Beriault, Daniel R.
    Delaney, Sarah R.
    CLINICAL BIOCHEMISTRY, 2024, 133
  • [8] Recent bionalytical methods for the determination of new psychoactive substances in biological specimens
    Simao, Ana Y.
    Antunes, Monica
    Marques, Hernani
    Rosado, Tiago
    Soares, Sofia
    Goncalves, Joana
    Barroso, Mario
    Andraus, Maristela
    Gallardo, Eugenia
    BIOANALYSIS, 2020, 12 (21) : 1557 - 1595
  • [9] Molecular Insights and Clinical Outcomes of Drugs of Abuse Adulteration: New Trends and New Psychoactive Substances
    Di Trana, Annagiulia
    Berardinelli, Diletta
    Montanari, Eva
    Berretta, Paolo
    Basile, Giuseppe
    Huestis, Marilyn A.
    Busardo, Francesco Paolo
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2022, 23 (23)
  • [10] A data-independent acquisition workflow for qualitative screening of new psychoactive substances in biological samples
    Kinyua, Juliet
    Negreira, Noelia
    Ibanez, Maria
    Bijlsma, Lubertus
    Hernandez, Felix
    Covaci, Adrian
    van Nuijs, Alexander L. N.
    ANALYTICAL AND BIOANALYTICAL CHEMISTRY, 2015, 407 (29) : 8773 - 8785